BPG is committed to discovery and dissemination of knowledge
Cited by in CrossRef
Number Cited Articles
1
Melvin J. Rivera, Bryan Do, Jeffrey C. Bryan, Terri Lynn Shigle, Rina Patel. Oncologic Critical Care2019; : 1 doi: 10.1007/978-3-319-74698-2_21-1
2
Debra H. Josephs, Danielle S. Fisher, James Spicer, Robert J. Flanagan. Clinical Pharmacokinetics of Tyrosine Kinase InhibitorsTherapeutic Drug Monitoring 2013; : 1 doi: 10.1097/FTD.0b013e318292b931
3
F. Alessandrino, S.H. Tirumani, K.M. Krajewski, A.B. Shinagare, J.P. Jagannathan, N.H. Ramaiya, D.N. Di Salvo. Imaging of hepatic toxicity of systemic therapy in a tertiary cancer centre: chemotherapy, haematopoietic stem cell transplantation, molecular targeted therapies, and immune checkpoint inhibitorsClinical Radiology 2017; 72(7): 521 doi: 10.1016/j.crad.2017.04.003
4
Stephanie A. Howard, Michael H. Rosenthal, Jyothi P. Jagannathan, Katherine M. Krajewski, Atul B. Shinagare, Nikhil H. Ramaiya, Sree Harsha Tirumani. Beyond the Vascular Endothelial Growth Factor Axis: Update on Role of Imaging in Nonantiangiogenic Molecular Targeted Therapies in OncologyAmerican Journal of Roentgenology 2015; 204(5): 919 doi: 10.2214/AJR.14.12876
5
Nelia Hernandez. Hepatotoxicity of New Antitumor AgentsCurrent Hepatology Reports 2017; 16(4): 293 doi: 10.1007/s11901-017-0381-7
6
Y. Maor, S. Malnick. Liver Injury Induced by Anticancer Chemotherapy and Radiation TherapyInternational Journal of Hepatology 2013; 2013: 1 doi: 10.1155/2013/815105
7
Joanna E. Barbara, Faraz Kazmi, Andrew Parkinson, David B. Buckley. Metabolism-Dependent Inhibition of CYP3A4 by Lapatinib: Evidence for Formation of a Metabolic Intermediate Complex with a Nitroso/Oxime Metabolite Formed via a Nitrone IntermediateDrug Metabolism and Disposition 2013; 41(5): 1012 doi: 10.1124/dmd.113.051151
8
Lishan Lin, Cen Xie, Zhiwei Gao, Xiaoyan Chen, Dafang Zhong. Metabolism and Pharmacokinetics of Allitinib in Cancer Patients: The Roles of Cytochrome P450s and Epoxide Hydrolase in its BiotransformationDrug Metabolism and Disposition 2014; 42(5): 872 doi: 10.1124/dmd.113.056341
9
David E. Kleiner. Macsween's Pathology of the Liver2018; : 673 doi: 10.1016/B978-0-7020-6697-9.00012-1
10
Noëmi Johanna Roos, Diell Aliu, Jamal Bouitbir, Stephan Krähenbühl. Lapatinib Activates the Kelch-Like ECH-Associated Protein 1-Nuclear Factor Erythroid 2-Related Factor 2 Pathway in HepG2 CellsFrontiers in Pharmacology 2020; 11 doi: 10.3389/fphar.2020.00944
11
Neil M. Iyengar, Monica N. Fornier, Steven M. Sugarman, Maria Theodoulou, Tiffany A. Troso-Sandoval, Gabriella M. D'Andrea, Pamela R. Drullinsky, Devika Gajria, Shari B. Goldfarb, Elizabeth A. Comen, Diana E. Lake, Shanu Modi, Tiffany A. Traina, Mario E. Lacouture, Melanie F. Chen, Sujata Patil, José Baselga, Larry Norton, Clifford A. Hudis, Chau T. Dang. A Pilot Study of Dose-Dense Paclitaxel With Trastuzumab and Lapatinib for Node-negative HER2-Overexpressed Breast CancerClinical Breast Cancer 2016; 16(2): 87 doi: 10.1016/j.clbc.2015.09.009
12
Jaymin J. Kathiriya, Ravi Ramesh Pathak, Eric Clayman, Bin Xue, Vladimir N. Uversky, Vrushank Davé. Presence and utility of intrinsically disordered regions in kinasesMol. BioSyst. 2014; 10(11): 2876 doi: 10.1039/C4MB00224E
13
Chalermrat Bunchorntavakul, K. Rajender Reddy. Drug HepatotoxicityClinics in Liver Disease 2017; 21(1): 115 doi: 10.1016/j.cld.2016.08.009
14
Jennifer E. Bissada, Vivian Truong, Arsany A. Abouda, Kahari J. Wines, Rachel D. Crouch, Klarissa D. Jackson. Interindividual Variation in CYP3A Activity Influences Lapatinib BioactivationDrug Metabolism and Disposition 2019; 47(11): 1257 doi: 10.1124/dmd.119.088823
15
Wimonchat Tangamornsuksan, Chuenjid Kongkaew, C. N. Scholfield, Suphat Subongkot, Manupat Lohitnavy. HLA-DRB1*07:01 and lapatinib-induced hepatotoxicity: a systematic review and meta-analysisThe Pharmacogenomics Journal 2020; 20(1): 47 doi: 10.1038/s41397-019-0092-2
16
J L Woodhead, K Yang, K L R Brouwer, S Q Siler, S H Stahl, J L Ambroso, D Baker, P B Watkins, B A Howell. Mechanistic Modeling Reveals the Critical Knowledge Gaps in Bile Acid–Mediated DILICPT Pharmacometrics Syst. Pharmacol. 2014; 3(7): e123 doi: 10.1038/psp.2014.21
17
Kirsty Wai-Chung Lee, Stephen Lam Chan. Hepatotoxicity of targeted therapy for cancerExpert Opinion on Drug Metabolism & Toxicology 2016; 12(7): 789 doi: 10.1080/17425255.2016.1190831
18
Melvin J. Rivera, Bryan Do, Jeffrey C. Bryan, Terri Lynn Shigle, Rina Patel. Oncologic Critical Care2020; : 201 doi: 10.1007/978-3-319-74588-6_21